Table 1.
Baseline characteristics of MM patients from which primary samples were obtained.
| MM patients (n = 15)a | |
|---|---|
| Age (median in years, IQR) | 70 (63–75.8) |
| Male sex (n, %) | 12 (80%) |
| M-protein (n, %) | |
| IgG kappa | 6 (40%) |
| IgG lambda | 1 (7%) |
| IgA kappa | 1 (7%) |
| IgA lambda | 1 (7%) |
| Light chain only | 4 (27%) |
| Unknown | 2 (13%) |
| Disease stage | |
| Newly diagnosed MM | 4 (27%) |
| Relapsed/refractory MM | 11 (73%) |
| Prior lines of treatment (median, IQR) | 5 (3.5–6) |
| Refractory tob (n, %) | |
| Lenalidomide | 8 (53%) |
| Bortezomib | 6 (40%) |
| Daratumumab | 8 (53%) |
a
From one patient with relapsed/refractory disease, two samples were obtained at different timepoints before and after daratumumab treatment.
b
Refractory disease is defined as progressive disease during therapy, no response (less than partial response), or progressive disease within 60 days of stopping treatment, according to the International Uniform Response Criteria for Multiple Myeloma.